美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Erythromycin	Tablet (Delayed Release)			Refer to USP			2013/10/31
Erythromycin Ethylsuccinate	Suspension	II (Paddle)	75	Monobasic Sodium Phosphate, pH 6.8 Buffer with 1% SLS Buffer w/ 1% SLS	900	10, 20, 30, 45 and 60	2004/01/27
Erythromycin Ethylsuccinate	Tablet			Refer to USP			2021/04/22
Erythromycin Ethylsuccinate	Oral granule			Develop a dissolution method			2016/06/30
Erythromycin Ethylsuccinate/Sulfisoxazole Acetyl	Granules for Oral Suspension			Develop a dissolution method			2010/09/02
Escitalopram Oxalate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Escitalopram Oxalate	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Eslicarbazepine Acetate	Tablet	II (Paddle)	100	Acetate Buffer, pH 4.5	1000	5, 10, 15, 20, 30 and 45	2015/08/27
Esomeprazole Magnesium	Capsule (Delayed Release Pellets)			Refer to USP			2015/08/27
Esomeprazole Magnesium	Tablet (Orally Disintegrating, Delayed Release)	II (Paddle)	Acid stage: 100; Buffer stage: 75	Acid stage: 0.1 N HCl; Buffer stage: Phosphate Buffer, pH 6.8	Acid stage: 300; Buffer stage: 1000	Acid stage: 120; Buffer stage: 5, 10, 20, 30 and 45	2021/04/22
Esomeprazole Magnesium	Tablet (Delayed Release)	II (Paddle)	100	Acid stage: 0.1 N HCl; Buffer stage: Phosphate Buffer, pH 6.8	Acid stage: 300; Buffer stage: 1000	Acid stage: 120; Buffer stage: 10, 20, 30, 45 and 60	2016/10/20
Esomeprazole Magnesium	For Oral Suspension (Delayed Release)	II (Paddle	100	Acid stage: 0.1 N HCl; Buffer stage: Sodium Phosphate Buffer, pH 6.8	Acid stage: 300; Buffer stage: 1000	Acid stage: 120; Buffer stage: 10, 20, 30, 45 and 60	2010/09/02
Estazolam	Tablet			Develop a dissolution method			2023/09/15
Esterified Estrogens	Tablet			Develop a dissolution method			2023/09/15
Estradiol	Vaginal Ring	Incubator shaker	130	0.9% Saline	250	1, 9, 16, 17, 18, 19, 45 days	2007/01/03
Estradiol	Vaginal Tablet	I (Basket)	40	Phosphate Buffer, pH 4.75 ± 0.05	500	1, 2, 3, 5, 8, 10 and 12 hours	2009/07/21
Estradiol	Vaginal Insert	III (Reciprocating Cylinder)	30 dips/min	0.1 N HCl with 0.5% SLS	250	30, 60, 90 and 120	2024/11/01
Estradiol (0.014 mg/24 hr)	Film, Transdermal (Extended Release)			Develop a method to characterize in vitro release			2010/10/28
Estradiol (0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr and 0.1 mg/24 hr)	Film, Transdermal (Extended Release)			Develop a method to characterize in vitro release			2010/10/28
Estradiol (E2); Norethindrone Acetate (NETA); Relugolix (Rel)	Tablet	II (Paddle)	50	E2 and NETA: 0.3% sodium dodecyl sulfate Rel: 50 mM citrate buffer, pH 5.5		10, 15, 20, 30, 45 and 60	2026/01/28